Trial record 15 of 15 for:    Open Studies | "Heroin Dependence"

Aprepitant Effects in Intravenous Heroin Dependence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by New York University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Stephen Ross, New York University
ClinicalTrials.gov Identifier:
NCT01527994
First received: January 9, 2012
Last updated: February 3, 2012
Last verified: February 2012
  Purpose

Current treatments for opioid addiction would benefit by the addition of a non-opioid based treatment medication. Recent behavioral studies have shown that the neurokinin-1 (NK1) receptor is involved in opioid reward and withdrawal. This study proposes to study a potential non-opioid treatment, the clinically available, FDA approved, NK1 antagonist aprepitant, in opioid addicted patients. Based on the unique behavioral and pharmacological characteristics of opioid addiction, and what is known of the currently employed treatments, the investigators propose that the therapeutic mechanism of any potential opioid addiction treatment medication must include the ability to reduce opioid withdrawal. This is of particular importance during treatment initiation (eg. detoxification). In addition, for long-term treatment and relapse prevention, it is important to manage drug craving and inhibit the rewarding effects of opioids if patients do experience a slip. Therefore, the investigators propose to study aprepitant using human models of opioid withdrawal, craving and acute opioid reward and reinforcement. The investigators will also include a neuro-economics choice procedure paradigm.


Condition Intervention Phase
Opioid Dependence
Drug: Aprepitant
Drug: Placebo pill
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Laboratory Evaluations of Aprepitant for the Treatment of Opioid Dependence: Inpatient Test

Resource links provided by NLM:


Further study details as provided by New York University:

Primary Outcome Measures:
  • Opioid Withdrawal [ Time Frame: 30 minutes pre-medication, 150 minutes post medication, 15 minutes post-challenge drug administration, 1 hour post- challenge drug administration, 2 hours post challenge drug administration and 3.5 hours post challenge drug administration ] [ Designated as safety issue: Yes ]
    On the 4 dosing days, opioid withdrawal will be measured using the Clinical Opiate Withdrawal Scale (COWS) and the Subjective Opioid Withdrawal Scale (SOWS) at the following time points: 30 minutes pre-medication, 150 minutes post medication, 15 minutes post-challenge drug administration, 1 hour post- challenge drug administration, 2 hours post challenge drug administration and 3.5 hours post challenge drug administration


Secondary Outcome Measures:
  • Opioid Intoxication [ Time Frame: 30 minutes pre-medication, 150 minutes post medication, 15 minutes post-challenge drug administration, 1 hour post- challenge drug administration, 2 hours post challenge drug administration and 3.5 hours post challenge drug administration ] [ Designated as safety issue: Yes ]
    On the 4 dosing days, opioid intoxication will be measured using the Visual Anaglog Scale (VAS)at the following time points: 30 minutes pre-medication, 150 minutes post medication, 15 minutes post-challenge drug administration, 1 hour post- challenge drug administration, 2 hours post challenge drug administration and 3.5 hours post challenge drug administration

  • Neuro-economic Choice Procedure [ Time Frame: 45 minutes post challenge drug dosing ] [ Designated as safety issue: Yes ]
    A neuro-economics collaborative team will perform a neuro-economic choice paradigm procedure at 45 minutes post challenge drug dosing to determine the relative proportion and amount of a further dose of drug at 3.5 hours post challenge drug administration versus receipt of a variable amount of money


Estimated Enrollment: 28
Study Start Date: January 2012
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aprepitant 125 mg
Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
Drug: Aprepitant
Aprepitant 125 mg oral tablets
Other Name: Brand name: Emend
Placebo Comparator: Placebo
Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
Drug: Placebo pill
Placebo oral pill- inactive compound

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects ranging in age from 18-55 years who are currently opioid dependent based on meeting DSM-IV criteria for dependence on heroin and who are either treatment or non-treatment seeking individuals.
  2. Use of intravenous heroin daily for a minimum of 45 days prior to study entry.
  3. Urine sample (+) for opioids and prior experience with i.v. drug injection.
  4. Female subjects who are not of childbearing potential, (i.e. post-hysterectomy, or two years post-menopausal) or who are of childbearing potential but will either abstain from heterosexual intercourse and/or practice a medically accepted form of contraception for the study duration.
  5. Subjects who have experienced significant opioid withdrawal and are familiar with its effects.
  6. Subjects who are willing to follow the protocol requirements, including methadone and study medication schedules, as evidenced by written informed consent and an ability to read, understand, and complete the study questionnaires.

Exclusion Criteria:

  1. Subjects with any significant current axis-1 psychiatric problems, other than those related to drug abuse and opioid dependence, based on a structured psychiatric interview, SCID or MINI, during the screening process.
  2. Subjects undergoing active treatment for any illness other than chronic stable medical conditions (Patients with HIV and/or taking anti-viral HIV medication without a manifestation of AIDS symptoms are allowed).
  3. Subjects with clinically significant abnormal findings as determined by medical history, physical examination, vital signs (blood pressure, heart rate, and respiration rate), 02 saturation measure,12-lead ECG, clinical laboratory tests (CBC, chemistry panel), urine drug screen, alcohol breath test, and urine pregnancy test (for females of childbearing potential only).
  4. Subjects who have any acute organ dysfunction or serious unstable disease states including symptomatic heart, renal or liver disease, COPD, sleep apnea, or encephalitis.
  5. Subjects with 02 saturation below 90% at screening.
  6. Subjects taking any concomitant medications (prescription and over-the-counter therapy) including psychotropic medications for the treatment of current major depression, schizophrenia, or mood disorders, as well as medications contraindicated for use with morphine, naltrexone, aprepitant, or methadone.
  7. Subjects who have received any investigational drug or treatment within the thirty (30) days preceding administration of study medication.
  8. Females who are nursing, pregnant (as confirmed by a positive urine pregnancy test), or at risk of becoming pregnant.
  9. Subjects allergic or intolerant to morphine, methadone, naloxone, or aprepitant.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01527994

Contacts
Contact: Stephen Ross, MD 212-562-4097 stephen.ross@nyumc.org
Contact: Krystallia Kalliontzi 212-562-5001 krystallia.kalliontzi@nyumc.org

Locations
United States, New York
Bellevue Hospital Center & the NYU School of Medicine Recruiting
New York, New York, United States, 10016
Contact: Stephen Ross, MD    212-562-4097    stephen.ross@nyumc.org   
Contact: Krystallia Kalliontzi    212-562-5001    krystallia.kalliontzi@nymc.org   
Principal Investigator: Stephen Ross, MD         
Sponsors and Collaborators
New York University
Investigators
Principal Investigator: Stephen Ross, MD NYU School of Medicine & Bellevue Hospital Center
  More Information

No publications provided

Responsible Party: Stephen Ross, Director, Division of Alcoholism & Drug Abuse, NYU/Bellevue Hospital Center, New York University
ClinicalTrials.gov Identifier: NCT01527994     History of Changes
Other Study ID Numbers: 09-0457, 5R01DA027151-02
Study First Received: January 9, 2012
Last Updated: February 3, 2012
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by New York University:
Aprepitant
Intravenous heroin dependence

Additional relevant MeSH terms:
Heroin Dependence
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Aprepitant
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents

ClinicalTrials.gov processed this record on April 17, 2014